AKT1 and central nervous system cancer: Notably, molecular analysis has identified concurrent somatic activation of the RAS/MAPK and PI3K/AKT signaling pathways in gliomas, which intriguingly overlap the signaling dysregulation seen in RASopathies (10–12).